Letrozole sensitizes breast cancer cells to ionizing radiation

Détails

ID Serval
serval:BIB_A4CAE8B80263
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Letrozole sensitizes breast cancer cells to ionizing radiation
Périodique
Breast Cancer Research
Auteur(s)
Azria  D., Larbouret  C., Cunat  S., Ozsahin  M., Gourgou  S., Martineau  P., Evans  D. B., Romieu  G., Pujol  P., Pelegrin  A.
ISSN
1465-542X
Statut éditorial
Publié
Date de publication
2005
Peer-reviewed
Oui
Volume
7
Numéro
1
Pages
R156-63
Notes
Journal Article
Résumé
INTRODUCTION: Radiotherapy (RT) is considered a standard treatment option after surgery for breast cancer. Letrozole, an aromatase inhibitor, is being evaluated in the adjuvant setting. We determined the effects of the combination of RT and letrozole in the aromatase-expressing breast tumour cell line MCF-7CA, stably transfected with the CYP19 gene. METHODS: Irradiations were performed using a cobalt-60 source with doses ranging from 0 to 4 Gy. Cells were incubated with androstenedione in the presence or absence of letrozole. Effects of treatment were evaluated using clonogenic assays, tetrazolium salt colorimetric (MTT) assays, and cell number determinations. Cell-cycle analyses were conducted using flow cytometry. RESULTS: The survival fraction at 2 Gy was 0.66 for RT alone and was 0.44 for RT plus letrozole (P = 0.02). Growth of MCF-7CA cells as measured by the cell number 6 days after radiotherapy (2 and 4 Gy) was decreased by 76% in those cells treated additionally with letrozole (0.7 microM) compared with those receiving radiotherapy alone (P = 0.009). Growth inhibition, assessed either by cell number (P = 0.009) or by the MTT assay (P = 0.02), was increased after 12 days of the combination treatment. Compared with radiation alone, the combination of radiation and letrozole produced a significant decrease in radiation-induced G2 phase arrest and a decrease of cells in the S phase, with cell redistribution in the G1 phase. CONCLUSIONS: These radiobiological results may form the basis for concurrent use of letrozole and radiation as postsurgical adjuvant therapy for breast cancer.
Mots-clé
Antineoplastic Agents/*pharmacology Aromatase/biosynthesis/genetics Breast Neoplasms/*pathology Cell Cycle/*drug effects/*radiation effects Cell Survival Female Flow Cytometry Humans Nitriles/*pharmacology Radiation-Sensitizing Agents/*pharmacology Radiotherapy, Adjuvant Transfection Triazoles/*pharmacology
Pubmed
Web of science
Open Access
Oui
Création de la notice
24/01/2008 18:16
Dernière modification de la notice
08/05/2019 23:10
Données d'usage